# Austral Capital

> Austral Capital is a VC fund in Santiago backing Software and Electronics. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Santiago, Chile
- Total investments: 10
- Last investment: Dec 2014
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/1382033
- X (Twitter): http://twitter.com/gonzalomiranda
- Website: http://www.australcap.com

Austral Capital is a venture capital firm that invests in leading technology services companies located in Chile, Colombia, Peru and Mexico that have the potential to accelerate their growth through expanded service and solution offerings in the region. The firm mainly invests in growth-stage companies that provide core digital platforms for thefinancial, retail and healthcare markets.

## Contacts

5 contacts available for Austral Capital. Shizune tracks 4 team members at Austral Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/austral-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 20% |
| Electronics | 2 | 20% |
| Enterprise Software | 2 | 20% |
| Information Technology | 2 | 20% |
| Fuel | 1 | 10% |

25 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 3 | 30% |
| Seed | 2 | 20% |
| Series A | 2 | 20% |
| Series B | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 40% |
| Chile | 3 | 30% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gonzalo Miranda | Founding Partner | 0 | https://shizune.co/investors/profile/gonzalo-miranda |
| Hiroshi Wald | Managing Director | 0 | https://shizune.co/investors/profile/hiroshi-wald |
| Mauricio Espinoza Navarrete | CFO | 0 | https://shizune.co/investors/profile/mauricio-espinoza-navarrete |
| Nicolas Zarges | Principal | 0 | https://shizune.co/investors/profile/nicolas-zarges |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Andes Biotechnologies | Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. |  |  | Dec 23, 2014 |  |
| Scopix | SCOPIX is the market leader in intelligent video analytics for retailers, CPG companies and manufactures. Our Real.Suite ™ family of cloud based solutions collects data and returns timely, actionable information via a web based portal to store personnel, regional managers and corporate executives to help them maximize the customer experiencethroughout the entire store. SCOPIX solutions are proven to enhance retail business operations, drive sales and maximize profits. | $4.8M |  | Jul 02, 2012 |  |
| Junar | Junar powers the Data Economy by delivering the easiest-to-use, cloud-based Open Data platform. For innovative organizations, Junar is the fastest way to publish data. The Junar platform enables businesses, governments, and organizations to free their data to drive new opportunities, collaboration, and transparency. Some of the world'sleading companies trust Junar with their most valuable assets: their data and the end users who are viewing and using it. | $1.2M | Seed | May 29, 2012 |  |
| Nimbic | Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula andPanasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy. | $444K |  | Jan 01, 2012 |  |
| Nimbic | Nimbic is a provider of SaaS-based, cloud computing electronic design automation (EDA) solutions. Nimbic enables high-speed and high-capacity 3D electromagnetic signal integrity, power integrity and EMI analysis field solutions for the microelectronics industry. Nimbic's global customers include Texas Instruments, Renesas, Toshiba, Tabula andPanasonic. Nimbic's nCloud solution facilitates efficient and robust chip-package-system co-design while significantly reducing time-to-market and costs. Nimbic's accelerated technology delivers unprecedented capacity handling, significantly faster speed than current methodologies, and the ability to span the entire design cycle in 3D IC, package and system simulations, while maintaining uncompromising Maxwell accuracy. | $6.9M | Series B | Jun 02, 2011 |  |
| Andes Biotechnologies | Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. |  |  | May 19, 2011 |  |
| Bio Architecture Lab | Bio Architecture Lab is a pioneer in the application of synthetic biology and enzyme design to the development of biofuels and renewable chemicals from aquafarmed, native macroalgae (seaweed), which is a low cost, scalable, and sustainable biomass. | $8M | Series A | Nov 23, 2009 |  |
| Atakama Labs | Atakama Labs is a developer, publisher and operator of social games, focused on meaningful games. They are making games that will make the world a better place, while entertaining and surprising their players. Their games tend to be free to play so that everyone can enjoy them. They develop primarily in Chile and publish their products across theglobe, both directly and together with partners, depending on the platform and territory. Atakama is backed by Austral Capital and the COPEC-UC Fund, two venture capital funds. |  | Seed | Aug 01, 2009 |  |
| Paperless | Paperless is an electronic receipts and electronic document management company in Latin America, processing over two billion documents per year for global enterprise businesses. |  | Series A | Apr 10, 2008 |  |
| Andes Biotechnologies | Andes Biotechnologies is a leading nucleic acid-based drug discovery and development company focused on solid tumor cancers. The Company has discovered two novel families of long non-coding RNAs: sense (S-RNA) and antisense (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.Theproprietary technology developed by Andes Biotechnologies is based on oligonucleotide drugs that target the novel long non-coding regulatory RNAs in tumor cells inducing apoptosis.Andes Biotechnologies has an active investigational new drug (IND) application in the United States and is currently engaged in the clinical development of its lead drug Andes-1537.Andes Biotechnologies is supported by a proven and experienced management team, a robust network of key national and international collaborators in the cancer field, and has an extensive intellectual property portfolio.Andes Biotechnologies was founded in 2008 and is located in Santiago, Chile. |  | Series B |  |  |

10 of 10 investments shown.

## Co-investors
- [Aurus](https://shizune.co/investors/profile/aurus) — VC Fund, 2 deals together
- [Band of Angels](https://shizune.co/investors/profile/band-of-angels) — VC Fund, 1 deal together
- [Fondo de Inversión Privado Copec-UC](https://shizune.co/investors/profile/copec-uc) — VC Fund, 1 deal together
- [Energy Capital Management](https://shizune.co/investors/profile/energy-capital-management) — VC Fund, 1 deal together
- [Washington Research Foundation](https://shizune.co/investors/profile/washington-research-foundation) — VC Fund, 1 deal together
- [XSeed Capital](https://shizune.co/investors/profile/xseed-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

### Similar country
- [CORFO](https://shizune.co/investors/profile/corfo) — VC Fund
- [Aster](https://shizune.co/investors/profile/aster-111d) — VC Fund
- [Fen Ventures](https://shizune.co/investors/profile/fen-ventures) — VC Fund

## Featured in investor lists
- [All VC Funds in Chile](https://shizune.co/investors/vc-funds-chile)
- [Software Investors in Chile](https://shizune.co/investors/software-investors-chile)
- [SaaS VC Funds in Chile](https://shizune.co/investors/saas-vc-funds-chile)
- [All Investors in Chile](https://shizune.co/investors/investors-chile)
- [Gaming Investors in Chile](https://shizune.co/investors/gaming-investors-chile)
- [Consumer VC Funds in Chile](https://shizune.co/investors/consumer-vc-funds-chile)

## FAQ

### What does Austral Capital invest in?

Austral Capital invests primarily in Software, Electronics and Enterprise Software startups, most often at Funding Round and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Austral Capital?

Public channels for Austral Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Austral Capital?

The team at Austral Capital includes Gonzalo Miranda (Founding Partner), Hiroshi Wald (Managing Director) and Mauricio Espinoza Navarrete (CFO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co